EP 1496923 A4 20051019 - CANCER IMMUNOTHERAPY
Title (en)
CANCER IMMUNOTHERAPY
Title (de)
IMMUNTHERAPIE GEGEN KREBS
Title (fr)
IMMUNOTHERAPIE DU CANCER
Publication
Application
Priority
US 0208983 W 20020322
Abstract (en)
[origin: WO03092717A1] A method for stimulating an immune response against IL-12R alpha 2 in a subject having or at risk for developing a disease having cells expressing IL-13R alpha 2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13R alpha 2 in the subject. A composition for stimulating an immune response agaist IL-13R alpha 2 in a subject having or at risk for developing a disease having cells expressing IL-13R alpha 2 includes an isolated agent that can stimulate immune response against IL-13 alpha 2.
IPC 1-7
A61K 38/00; A61K 39/00; A61K 31/70; A01K 43/04; C07K 14/00; C07K 16/00; C07K 17/00; C07K 1/00; C07K 2/00; C07K 4/00; C07K 7/00; A61P 35/00
IPC 8 full level
A61K 48/00 (2006.01); A61K 31/70 (2006.01); A61K 35/12 (2015.01); A61K 35/14 (2015.01); A61K 35/15 (2015.01); A61K 35/52 (2015.01); A61K 35/76 (2015.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC (source: EP US)
A61K 31/70 (2013.01 - EP); A61K 39/001119 (2018.08 - EP US); A61P 35/00 (2018.01 - EP); C07K 16/30 (2013.01 - EP); A61K 39/00 (2013.01 - EP); A61K 2039/5156 (2013.01 - EP); A61K 2039/53 (2013.01 - EP)
Citation (search report)
[X] WO 0158479 A1 20010816 - PENN STATE RES FOUND [US]
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 03092717 A1 20031113; AU 2002254348 A1 20031117; AU 2002254348 B2 20071206; CA 2480008 A1 20031113; CA 2480008 C 20151006; EP 1496923 A1 20050119; EP 1496923 A4 20051019; JP 2005526842 A 20050908
DOCDB simple family (application)
US 0208983 W 20020322; AU 2002254348 A 20020322; CA 2480008 A 20020322; EP 02723576 A 20020322; JP 2004500900 A 20020322